By Mark H. Wilcox, MD, FRCPath

Evidence continues to accumulate on the increased relative efficacy of some therapies for Clostridioides difficile infection (CDI), especially with respect to the prevention of recurrent infection. There are 4 currently approved therapeutic agents for managing CDI: 2 older antibiotics, metronidazole and vancomycin, and 2 newer options, the antibiotic fidaxomicin (Dificid, Merck) and, most recently, a monoclonal antibody against 1 of the 2 major C. difficile toxins